These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 19438394)

  • 1. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.
    Hartzell JD; Neff R; Ake J; Howard R; Olson S; Paolino K; Vishnepolsky M; Weintrob A; Wortmann G
    Clin Infect Dis; 2009 Jun; 48(12):1724-8. PubMed ID: 19438394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrotoxicity associated with intravenous colistin.
    Tarchini G
    Clin Infect Dis; 2009 Dec; 49(11):1773; author reply 1773. PubMed ID: 19891573
    [No Abstract]   [Full Text] [Related]  

  • 3. Nephrotoxicity associated with intravenous colistin in critically ill patients.
    Doshi NM; Mount KL; Murphy CV
    Pharmacotherapy; 2011 Dec; 31(12):1257-64. PubMed ID: 22122186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of acute kidney injury associated with intravenous colistin treatment.
    Kwon JA; Lee JE; Huh W; Peck KR; Kim YG; Kim DJ; Oh HY
    Int J Antimicrob Agents; 2010 May; 35(5):473-7. PubMed ID: 20089383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system.
    Pogue JM; Lee J; Marchaim D; Yee V; Zhao JJ; Chopra T; Lephart P; Kaye KS
    Clin Infect Dis; 2011 Nov; 53(9):879-84. PubMed ID: 21900484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and Risk Factors for Colistin-Associated Nephrotoxicity.
    Temocin F; Erdinc S; Tulek N; Demirelli M; Bulut C; Ertem G
    Jpn J Infect Dis; 2015; 68(4):318-20. PubMed ID: 25720641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrotoxicity of intravenous colistin: a prospective evaluation.
    Falagas ME; Fragoulis KN; Kasiakou SK; Sermaidis GJ; Michalopoulos A
    Int J Antimicrob Agents; 2005 Dec; 26(6):504-7. PubMed ID: 16280245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.
    Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL
    Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and risk factors of colistin-induced nephrotoxicity.
    Kim J; Lee KH; Yoo S; Pai H
    Int J Antimicrob Agents; 2009 Nov; 34(5):434-8. PubMed ID: 19726164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction.
    Turkoglu M; Dizbay M; Ciftçi A; Aksakal FN; Aygencel G
    Int J Antimicrob Agents; 2012 Feb; 39(2):142-5. PubMed ID: 22115538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes.
    Kwon KH; Oh JY; Yoon YS; Jeong YJ; Kim KS; Shin SJ; Chung JW; Huh HJ; Chae SL; Park SY
    Int J Antimicrob Agents; 2015 Jun; 45(6):605-9. PubMed ID: 25772644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria.
    Pintado V; San Miguel LG; Grill F; Mejía B; Cobo J; Fortún J; Martín-Dávila P; Moreno S
    J Infect; 2008 Mar; 56(3):185-90. PubMed ID: 18280570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis.
    Falagas ME; Sideri G; Vouloumanou EK; Papadatos JH; Kafetzis DA
    Pediatr Infect Dis J; 2009 Feb; 28(2):123-7. PubMed ID: 19116601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrotoxicity associated with the use of intravenous colistin.
    Santamaría C; Mykietiuk A; Temporiti E; Stryjewski ME; Herrera F; Bonvehi P
    Scand J Infect Dis; 2009; 41(10):767-9. PubMed ID: 19685371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.
    Cheng CY; Sheng WH; Wang JT; Chen YC; Chang SC
    Int J Antimicrob Agents; 2010 Mar; 35(3):297-300. PubMed ID: 20045293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity.
    Oliveira MS; Prado GV; Costa SF; Grinbaum RS; Levin AS
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):431-4. PubMed ID: 19733029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colistin-induced Nephrotoxicity in a Tertiary Teaching Hospital.
    Al-Abdulkarim DA; Alzuwayed OA; Al Ammari M; Al Halwan S; Al Maklafi N; Thomas A
    Saudi J Kidney Dis Transpl; 2020; 31(5):1057-1061. PubMed ID: 33229769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients.
    Falagas ME; Rafailidis PI; Ioannidou E; Alexiou VG; Matthaiou DK; Karageorgopoulos DE; Kapaskelis A; Nikita D; Michalopoulos A
    Int J Antimicrob Agents; 2010 Feb; 35(2):194-9. PubMed ID: 20006471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergent renal dysfunction with colistin pharmacotherapy.
    Collins JM; Haynes K; Gallagher JC
    Pharmacotherapy; 2013 Aug; 33(8):812-6. PubMed ID: 23606349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium.
    Hassan MM; Gaifer Z; Al-Zakwani IS
    Int J Clin Pharm; 2018 Apr; 40(2):444-449. PubMed ID: 29542034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.